A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Connect Investigative Site 01, Beijing

Connect Investigative Site 41, Beijing

Connect Investigative Site 14, Fuzhou

Connect Investigative Site 25, Fuzhou

Connect Investigative Site 03, Guangzhou

Connect Investigative Site 11, Guangzhou

Connect Investigative Site 13, Guangzhou

Connect Investigative Site 20, Guangzhou

Connect Investigative Site 22, Shenzhen

Connect Investigative Site 31, Nanning

Connect Investigative Site 16, Haikou

Connect Investigative Site 17, Haikou

Connect Investigative Site 19, Nanyang

Connect Investigative Site 27, Wuhan

Connect Investigative Site 28, Yichang

Connect Investigative Site 26, Changsha

Connect Investigative Site 34, Nanjing

Connect Investigative Site 39, Suzhou

Connect Investigative Site 05, Zhenjiang

Connect Investigative Site 29, Shenyang

Connect Investigative Site 40, Jiangxi

Connect Investigative Site 24, Baotou

Connect Investigative Site 18, Yinchuan

Connect Investigative Site 30, Dongying

Connect Investigative Site 21, Jinan

Connect Investigative Site 35, Jinan

Connect Investigative Site 36, Shanghai

Connect Investigative Site 10, Taiyuan

Connect Investigative Site 06, Xi’an

Connect Investigative Site 15, Yuncheng

Connect Investigative Site 23, Chengdu

Connect Investigative Site 02, Tianjin

Connect Investigative Site 09, Ürümqi

Connect Investigative Site 07, Hangzhou

Connect Investigative Site 08, Hangzhou

Connect Investigative Site 33, Hangzhou

Connect Investigative Site 37, Hangzhou

Connect Investigative Site 32, Ningbo